Third-Generation EGFR Inhibitors’ Safety Profiles Under Scrutiny At ASCO
This article was originally published in The Pink Sheet Daily
Executive Summary
In stark contrast with the first generation of EGFR inhibitors, Clovis’ CO-1386 has rash rates that are on par with placebo. But the drug must contend with high rates of excess blood sugar as well as QTc prolongation. AstraZeneca’s AZD9291 has its own safety issues, but coming efficacy results should carry the class.
You may also be interested in...
Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
With Gilotrif sales building over time, private Boehringer Ingelheim turns its focus to broad development program for its third-generation EGFR inhibitor olmutinib, with ambition to become a leader in lung cancer.
Broader Indications For Tarceva As Astellas Scales Back In The U.S.
The Japanese pharma is consolidating its U.S. operations, including the shuttering of OSI, where Tarceva initially was developed, as the cancer drug gains another indication with a companion diagnostic.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).